Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811830 | 0.82 | TDP1 (0.45) | NAMPTPRMT3EPHX1KDM1AMAOA | |
| SCHEMBL9893063 | 0.82 | BRD4 (0.43) | NAMPTPRMT3EPHX1KDM1AMAOA | |
| SCHEMBL28691672 | 0.81 | EPHX1 (0.53) | EPHX1CYP2D6NPC1RAB9AL3MBTL1 | |
| SCHEMBL17493719 | 0.81 | EPHX1 (0.58) | PRMT3EPHX1CYP2D6NPC1RAB9A | |
| SCHEMBL13070014 | 0.81 | ALDH1A1 (0.42) | NAMPTPRMT3EPHX1KDM1AMAOA | |
| SCHEMBL15248911 | 0.81 | NAMPT (0.40) | NAMPTPRMT3EPHX1KDM1AMAOA | |
| SCHEMBL25925311 | 0.79 | MEN1 (0.45) | NAMPTPRMT3EPHX1ALDH1A1 | |
| SCHEMBL9956855 | 0.79 | CYP2D6 (0.53) | NAMPTEPHX1BRD4ALDH1A1EPHX2 | |
| SCHEMBL6062059 | 0.79 | EPHX1 (0.61) | EPHX1EPHX2CYP2D6NPC1RAB9A | |
| SCHEMBL9891910 | 0.78 | SIGMAR1 (0.43) | NAMPTPRMT3EPHX1BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-2640719-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190855-A1 | CDK INHIBITORS AND METHODS OF USE THEREOF | CDK3, CDK8, CDK6 | NAMPT 812/4885PRMT3 397/4885EPHX1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.